Reltecimod
- Generic Name
- Reltecimod
- Drug Type
- Small Molecule
- Chemical Formula
- C46H72N10O15S
- CAS Number
- 1447799-33-8
- Unique Ingredient Identifier
- U00J02UY29
- Background
Reltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections).
Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
- Conditions
- Necrotizing Soft Tissue InfectionPeritonitisAcute Kidney Injury
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Atox Bio Ltd
- Target Recruit Count
- 58
- Registration Number
- NCT03403751
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸UCSD Medical Center, San Diego, California, United States
🇺🇸University of Missouri, Columbia, Missouri, United States
Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Atox Bio Ltd
- Target Recruit Count
- 43
- Registration Number
- NCT01417780
- Locations
- 🇺🇸
San Francisco General Hospital, San Francisco, California, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
AB103 Peptide Antagonist in Healthy Volunteers
- First Posted Date
- 2010-07-21
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Atox Bio Ltd
- Target Recruit Count
- 25
- Registration Number
- NCT01166984
- Locations
- 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.